February 1, 1986Clinical Science

Antihypertensive effects of S9490-3, a new converting enzyme inhibitor, in the conscious spontaneously hypertensive rat

View Full Paper

Ask AI

Bookmark

Why the study?

Does S9490-3 reduce blood pressure in spontaneously hypertensive rats?

Population

Conscious, unrestrained adult spontaneously hypertensive rats (SHR)

Comparison

S9490-3 administered as a single intravenous… vs Control animals

Design

Preclinical

Follow-up

Up to 12 days

Authors

CBC. BarrèsUniversité Côte d'Azur CCCatherine CeruttiUniversité Claude Bernard Lyon 1 CPC. Z. PaultreUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Premature for clinical use in hypertension; leaves open translation of S9490-3 efficacy to human trials.

Structured PICO

Does S9490-3 reduce blood pressure in spontaneously hypertensive rats?

Population

Conscious, unrestrained adult spontaneously hypertensive rats (SHR)

Intervention

S9490-3 (converting enzyme inhibitor) administered as a single intravenous dose (2 mg/kg) or chronic oral treatment (1 mg/kg/24 h for 12 days)

Comparator

Control animals

Outcome

Intra-aortic systolic and diastolic blood pressuresurrogate

S9490-3, a novel converting enzyme inhibitor, effectively lowers blood pressure and reduces left ventricular weight in a spontaneously hypertensive rat model.

Cite This Study

Barrès et al. (1986) studied this question.

synapsesocial.com/papers/6a7150ca5d37378ac1de77d5 https://doi.org/10.1042/cs0700167

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Antihypertensive effects of S9490-3, a new converting enzyme inhibitor, in the conscious spontaneously hypertensive rat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Antihypertensive effects of S9490-3, a new converting enzyme inhibitor, in the conscious spontaneously hypertensive rat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider